Income Statement Presentation 2023

2022: Underlying business with strong momentum at year-end % CER Pharma Quarterly sales evolution 2021-2022 % CER Diagnostics Quarterly sales evolution 2021-2022 +55% +55% +48% +55% +45% +45% +35% +35% +31% +24% +25% +25% +17% +18% +14% +15% +15% +9% +9% +8% +7% +4% +5% +6% +6% +3% +5% +2% +5% +11% +7% +5% +8% +10% -5% -9% +2% 0% -5% 0% -1% -3% -6% -4% -13% -9% -15% -15% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2021 vs. 2020 2022 vs. 2021 2021 vs. 2020 2022 vs. 2021 -Pharma Pharma Underlying business' Diagnostics Diagnostics Base business Growth rates at CER (Constant Exchange Rates); 1 Excl. Ronapreve and total Actemra Roche 12

View entire presentation